|
DK2350075T3
(da)
|
2008-09-22 |
2014-05-26 |
Array Biopharma Inc |
Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
|
|
EP2387563B2
(en)
|
2009-01-16 |
2022-04-27 |
Exelixis, Inc. |
Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
DK2918588T3
(en)
|
2010-05-20 |
2017-08-28 |
Array Biopharma Inc |
Macrocyclic compounds as TRK kinase inhibitors
|
|
FI2621481T4
(fi)
|
2010-09-27 |
2023-01-13 |
|
Met- ja vegf-kaksoisestäjiä kastraatioresistentin eturauhassyövän ja osteoblastisten luun etäispesäkkeiden hoitamiseen
|
|
EP4019498A1
(en)
|
2011-02-10 |
2022-06-29 |
Exelixis, Inc. |
Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
|
|
MX351133B
(es)
|
2011-09-22 |
2017-10-03 |
Exelixis Inc |
Metodo para tratar osteoporosis.
|
|
AR088483A1
(es)
|
2011-10-20 |
2014-06-11 |
Exelixis Inc |
Proceso para preparar derivados de quinolina
|
|
EP2844254A1
(en)
|
2012-05-02 |
2015-03-11 |
Exelixis, Inc. |
A dual met - vegf modulator for treating osteolytic bone metastases
|
|
CN104703600A
(zh)
*
|
2012-09-07 |
2015-06-10 |
埃克塞里艾克西斯公司 |
用于治疗肺腺癌的met、vegfr和ret的抑制剂
|
|
MX366003B
(es)
*
|
2013-03-15 |
2019-06-24 |
Exelixis Inc |
Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida.
|
|
ES2927651T3
(es)
|
2013-04-04 |
2022-11-10 |
Exelixis Inc |
Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
|
|
EP3738952A1
(en)
|
2014-02-14 |
2020-11-18 |
Exelixis, Inc. |
Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
|
|
JP6666849B2
(ja)
|
2014-03-17 |
2020-03-18 |
エグゼリクシス， インコーポレイテッド |
カボザンチニブ製剤の投与
|
|
WO2015161277A1
(en)
*
|
2014-04-18 |
2015-10-22 |
Blueprint Medicines Corporation |
Met fusions
|
|
CN106488768A
(zh)
*
|
2014-04-25 |
2017-03-08 |
埃克塞里艾克西斯公司 |
治疗肺腺癌的方法
|
|
CN104788372B
(zh)
*
|
2014-07-25 |
2018-01-30 |
上海圣考医药科技有限公司 |
一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
|
|
EA033834B1
(ru)
|
2014-07-31 |
2019-11-29 |
Exelixis Inc |
Способ получения кабозантиниба, меченного фтором-18, и его аналогов
|
|
MA40457A
(fr)
|
2014-08-05 |
2017-06-14 |
Exelixis Inc |
Combinaison de médicaments pour traiter le myélome multiple
|
|
TWI767858B
(zh)
|
2014-11-16 |
2022-06-11 |
美商亞雷生物製藥股份有限公司 |
(S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
|
|
US10202365B2
(en)
|
2015-02-06 |
2019-02-12 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
|
|
PT3322706T
(pt)
|
2015-07-16 |
2021-03-08 |
Array Biopharma Inc |
Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
|
|
SG11201803438XA
(en)
|
2015-10-26 |
2018-05-30 |
Univ Colorado Regents |
Point mutations in trk inhibitor-resistant cancer and methods relating to the same
|
|
IL288519B2
(en)
|
2015-11-02 |
2023-09-01 |
Blueprint Medicines Corp |
inhibitors of ret
|
|
US10183928B2
(en)
|
2016-03-17 |
2019-01-22 |
Blueprint Medicines Corporation |
Inhibitors of RET
|
|
PE20181888A1
(es)
|
2016-04-04 |
2018-12-11 |
Loxo Oncology Inc |
Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
|
|
JP7057343B2
(ja)
|
2016-04-04 |
2022-04-19 |
ロクソ オンコロジー， インコーポレイテッド |
小児癌の処置方法
|
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
|
US11141413B2
(en)
|
2016-04-15 |
2021-10-12 |
Exelixis, Inc. |
Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
|
|
EP3454886A1
(en)
|
2016-05-13 |
2019-03-20 |
Instituto de Medicina Molecular |
Methods of treating diseases associated with ilc3 cells
|
|
HUE053643T2
(hu)
|
2016-05-18 |
2021-07-28 |
Loxo Oncology Inc |
(S)-N-(5 -((R)-2-(2,5-difluor-fenil)-pirrolidin-1-il)-pirazolo[1,5-A] pirimidin-3-il)-3-hidroxi-pirrolidin-1-karboxamid elõkészítése
|
|
WO2018017983A1
(en)
|
2016-07-22 |
2018-01-25 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to ret
|
|
WO2018022761A1
(en)
|
2016-07-27 |
2018-02-01 |
Blueprint Medicines Corporation |
Substituted cyclopentane-amides for treating disorders related to ret
|
|
JOP20190077A1
(ar)
|
2016-10-10 |
2019-04-09 |
Array Biopharma Inc |
مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
|
|
TWI704148B
(zh)
|
2016-10-10 |
2020-09-11 |
美商亞雷生物製藥股份有限公司 |
作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
|
WO2018136661A1
(en)
|
2017-01-18 |
2018-07-26 |
Andrews Steven W |
SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
|
|
WO2018136663A1
(en)
|
2017-01-18 |
2018-07-26 |
Array Biopharma, Inc. |
Ret inhibitors
|
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
|
EP3674325A4
(en)
|
2017-08-21 |
2021-11-03 |
Taiho Pharmaceutical Co., Ltd. |
FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN
|
|
TWI791053B
(zh)
|
2017-10-10 |
2023-02-01 |
美商亞雷生物製藥股份有限公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
|
|
TWI812649B
(zh)
|
2017-10-10 |
2023-08-21 |
美商絡速藥業公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
|
|
TWI802635B
(zh)
|
2018-01-18 |
2023-05-21 |
美商亞雷生物製藥股份有限公司 |
作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
|
|
WO2019143994A1
(en)
|
2018-01-18 |
2019-07-25 |
Array Biopharma Inc. |
Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
|
|
CN111630054B
(zh)
|
2018-01-18 |
2023-05-09 |
奥瑞生物药品公司 |
作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
|
|
EP4647127A3
(en)
|
2018-01-26 |
2025-12-17 |
Exelixis, Inc. |
Compounds for the treatment of kinase-dependent disorders
|
|
HRP20240124T1
(hr)
|
2018-04-03 |
2024-04-12 |
Blueprint Medicines Corporation |
Inhibitori za ret za uporabu u liječenju raka koji ima ret alteraciju
|
|
CN115569137A
(zh)
|
2018-06-15 |
2023-01-06 |
汉达癌症医药责任有限公司 |
激酶抑制剂的盐类及其组合物
|
|
CN110862397A
(zh)
*
|
2018-08-27 |
2020-03-06 |
北京赛特明强医药科技有限公司 |
二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用
|
|
WO2020055672A1
(en)
|
2018-09-10 |
2020-03-19 |
Array Biopharma Inc. |
Fused heterocyclic compounds as ret kinase inhibitors
|
|
US12448366B2
(en)
|
2020-05-29 |
2025-10-21 |
Rigel Pharmaceuticals, Inc. |
Solid forms of pralsetinib
|
|
DE102020005002A1
(de)
*
|
2020-08-17 |
2022-02-17 |
Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh |
Mittel zur Therapie von Tumorerkrankungen
|
|
US20240270855A1
(en)
|
2021-06-03 |
2024-08-15 |
Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud |
Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit
|
|
CN114354789B
(zh)
*
|
2021-12-27 |
2023-08-29 |
深圳海王医药科技研究院有限公司 |
一种同时测定卡博替尼类似物及其有关物质的方法
|
|
WO2023230770A1
(en)
*
|
2022-05-30 |
2023-12-07 |
Suzhou Singleron Biotechnologies Co., Ltd. |
Methods of lung adenocarcinoma treatment with non anti-luad drugs or compounds
|
|
AU2024215796A1
(en)
|
2023-01-31 |
2025-05-15 |
Handa Oncology, Llc |
Improved cabozantinib compositions and methods of use
|